Susquehanna International Group
BCLI

Susquehanna International Group’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Susquehanna International Group’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-8,493
Closed -$29.3K – 12174
2024
Q3 		$29.3K Sell
8,493
-120
-1% -$566 ﹤0.01% 11537
2024
Q2 		$43.9K Buy
8,613
+7,760
+910% +$58.2K ﹤0.01% 11463
2024
Q1 		$7.17K Buy
+853
New +$4.69K ﹤0.01% 11937
2023
Q3 		– Sell
-1,987
Closed -$61.4K – 12009
2023
Q2 		$61.4K Sell
1,987
-7,286
-79% -$302K ﹤0.01% 11246
2023
Q1 		$459K Buy
9,273
+2,706
+41% +$78.5K ﹤0.01% 8773
2022
Q4 		$162K Sell
6,567
-18,773
-74% -$702K ﹤0.01% 10410
2022
Q3 		$1.68M Sell
25,340
-7,427
-23% -$372K ﹤0.01% 5308
2022
Q2 		$1.36M Buy
32,767
+16,307
+99% +$734K ﹤0.01% 5787
2022
Q1 		$830K Buy
16,460
+607
+4% +$29.8K ﹤0.01% 7617
2021
Q4 		$951K Sell
15,853
-9,460
-37% -$466K ﹤0.01% 7429
2021
Q3 		$1.25M Sell
25,313
-12,100
-32% -$637K ﹤0.01% 6973
2021
Q2 		$2.13M Buy
37,413
+28,046
+299% +$1.5M ﹤0.01% 5768
2021
Q1 		$538K Sell
9,367
-933
-9% -$70.5K ﹤0.01% 9294
2020
Q4 		$699K Sell
10,300
-8,780
-46% -$1.2M ﹤0.01% 7540
2020
Q3 		$4.84M Buy
19,080
+693
+4% +$142K ﹤0.01% 3098
2020
Q2 		$3.09M Sell
18,387
-20
-0.1% -$2.16K ﹤0.01% 3749
2020
Q1 		$1.28M Buy
+18,407
New +$1.44M ﹤0.01% 4814
2019
Q2 		– Sell
-807
Closed -$53K – 10204
2019
Q1 		$53K Buy
+807
New +$45.9K ﹤0.01% 8456
2018
Q3 		– Sell
-727
Closed -$43K – 9201
2018
Q2 		$43K Buy
+727
New +$42.8K ﹤0.01% 9308
2017
Q4 		– Sell
-1,973
Closed -$122K – 9231
2017
Q3 		$122K Buy
1,973
+153
+8% +$9.9K ﹤0.01% 8289
2017
Q2 		$114K Sell
1,820
-2,233
-55% -$138K ﹤0.01% 8625
2017
Q1 		$258K Buy
+4,053
New +$211K ﹤0.01% 7600
2015
Q4 		– Sell
-1,253
Closed -$43K – 9404
2015
Q3 		$43K Buy
+1,253
New +$58.9K ﹤0.01% 9396

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 22.73% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $488M AUM 17.59% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Susquehanna International Group's BCLI Position: Q2 2024 in Review

Susquehanna International Group sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q2 2024, closing a stake of 1,770 shares — an estimated $13.3K sold.

Susquehanna International Group first reported a position in BCLI in Q1 2016 and held it in 21 quarters. The position peaked at $1.68M in Q4 2020. 48 funds tracked by Wall St. Rank hold BCLI as of Q2 2024.

  • Susquehanna International Group reported no remaining BRAINSTORM CELL THERAPUTC position as of Q2 2024 after selling out during the quarter.
  • Susquehanna International Group sold 1,770 BRAINSTORM CELL THERAPUTC shares in Q2 2024, an estimated $13.3K.
  • Susquehanna International Group first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2016 and held it in 21 quarters.
  • Susquehanna International Group's BRAINSTORM CELL THERAPUTC position peaked at $1.68M in Q4 2020.
  • 48 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q2 2024.

Based on Susquehanna International Group's 13F filing for Q2 2024, filed 15 Aug 2024.